COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL, CAR-T) FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN GREECE

被引：0
|
作者：
Loupas, M. A. [1 ]
Theodoratou, D. [2 ]
Kourlaba, G. [1 ]
机构：
[1] Econcare LP, Athens A1, Greece
[2] Gilead Sci Hellas, Palaio Faliro, Greece
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE298
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [31] Confirmation of the good real-life effectiveness of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphomas
    Jules, Higue
    HEMATOLOGIE, 2023, 29 (04): : 224 - 225
  • [32] BREXUCABTAGENE AUTOLEUCEL FOR ADULT PATIENTS WITH REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA: COST-EFFECTIVENESS IN THE CLINICAL SUBSETS
    Marchetti, Monia
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 198 - 198
  • [33] Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement
    Lionel, Anath C.
    Gurumurthi, Ashwath
    Fetooh, Ahmed
    Eldaya, Rami
    Ahmed, Sairah
    Iyer, Swaminathan P.
    Nastoupil, Loretta J.
    Westin, Jason
    Nair, Ranjit
    Fayad, Luis
    Malpica, Luis
    Tummala, Sudhakar
    Flowers, Christopher
    Neelapu, Sattva S.
    Wang, Michael L.
    Jain, Preetesh
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 669 - 673
  • [34] Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)
    Gupta, Vishal K.
    Roloff, Gregory W.
    Muffly, Lori S.
    Aldoss, Ibrahim
    Kopmar, Noam E.
    Lin, Chenyu
    Dekker, Simone E.
    Jeyakumar, Nikeshan
    O'Connor, Timothy E.
    Zhang, Amy
    Miller, Katharine
    Dykes, Kaitlyn C.
    Ahmed, Mohamed
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Dholaria, Bhagirathbhai
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Mathews, John
    Shaughnessy, Paul
    Logan, Aaron C.
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    O'Dwyer, Kristen M.
    Tsai, Stephanie B.
    Sasine, Joshua
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Stock, Wendy
    Galal, Ahmed
    Pullarkat, Vinod
    Cassaday, Ryan D.
    Shah, Bijal D.
    Faramand, Rawan
    BLOOD, 2023, 142
  • [35] Real-World Outcomes of Brexucabtagene Autoleucel ( brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry
    Bezerra, Evandro
    Itani, Taha
    Wudhikarn, Kistada
    Perales, Miguel-Angel
    Yang, Yang
    Gergis, Usama
    Aribi, Ahmed
    Hill, LaQuisa C.
    Jain, Nitin
    Leonard, Jessica T.
    Lutfi, Forat
    Kim, Soyoung
    Bye, Matthew
    Wang, Hai-Lin
    Hadjivassileva, Tsveta
    Nikolaenko, Liana
    Kloos, Ioana
    Abdeldaim, Amina
    Dalton, David
    Xu, Hairong
    Pasquini, Marcelo
    Kebriaei, Partow
    BLOOD, 2023, 142
  • [36] Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China
    Lin, Ziyi
    Zuo, Chenyu
    Jiang, Yifan
    Su, Wen
    Yao, Xing
    Man, Yu
    Wu, Qiong
    Xuan, Jianwei
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 41 - 48
  • [37] Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis
    Hess, Georg
    Vucinic, Vladan
    Rejeski, Kai
    Aydilek, Enver
    Simon, Linda
    Penack, Olaf
    Koenecke, Christian
    von Bonin, Malte
    von Tresckow, Bastian
    Fehr, Martin
    Pott, Christiane
    Stilgenbauer, Stephan
    Leng, Corinna
    Schroers, Roland
    Duell, Johannes
    Marks, Reinhard
    Mueller, Fabian
    Brunnberg, Uta
    Kerkhoff, Andrea
    Ohler, Anke
    Drouet, Eva-Maria Wagner
    Schmidtmann, Irene
    Theobald, Matthias
    Dreyling, Martin
    Dreger, Peter
    BLOOD, 2023, 142
  • [38] Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States
    Simons, Claire L.
    Malone, Daniel
    Wang, Michael
    Maglinte, Gregory A.
    Inocencio, Tim
    Wade, Sally W.
    Bennison, Craig
    Shah, Bijal
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 421 - 431
  • [39] COST-EFFECTIVENESS OF RELMACABTAGENE AUTOLEUCEL (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) VS SALVAGE CHEMOTHERAPY FOR CHINESE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS
    Lin, Z.
    Zuo, C.
    Jiang, Y.
    Su, W.
    Yao, X.
    Man, Y.
    Wu, Q.
    Guo, Z.
    Su, F.
    Xuan, J.
    VALUE IN HEALTH, 2022, 25 (12) : S62 - S63
  • [40] Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
    OReilly, Maeve A.
    Wilson, William
    Burns, David
    Kuhnl, Andrea
    Seymour, Frances
    Uttenthal, Ben
    Besley, Caroline
    Alajangi, Rajesh
    Creasey, Thomas
    Paneesha, Shankara
    Elliot, Johnathon
    Arias, Carlos Gonzalez
    Iyengar, Sunil
    Wilson, Matthew R.
    Delaney, Alison
    Rubio, Lourdes
    Lambert, Jonathan
    Begg, Khalil
    Boyle, Stephen
    Cheok, Kathleen P. L.
    Collins, Graham P.
    Roddie, Claire
    Johnson, Rod
    Sanderson, Robin
    HEMASPHERE, 2024, 8 (06):
12345